Soleno Therapeutics News and Activities

Presence

Soleno Therapeutics is a biotechnology company that develops medicines for rare diseases. Its main products and services include drug development and clinical programs for patients, healthcare providers, and specialty care markets.

Soleno Therapeutics products and services overview:

Rare disease therapies
Drug development
Clinical research
Biotechnology services

Revenue: ~$0 million

Employees: 85

Headquarters: Redwood City, United States (USA)

Soleno Therapeutics is owned by Neurocrine Biosciences.

Neurocrine Biosciences is one of the...

Neurocrine Biosciences is a company listed under the stock ticker NBIX (US).

Acquisition, funding and merger involving Neurocrine Biosciences.

Neurocrine Biosciences has acquired Soleno Therapeutics (posted on May 18 2026).
Neurocrine Biosciences has announced the acquisition of Soleno Therapeutics (posted on April 7 2026).

Executives

View the org chart displaying its 28 main executives

Most searched biographies at Soleno Therapeutics

Popular executive movements at Soleno Therapeutics

Karen Choy who was Senior Manager, Quality Control and Analytical Development, becomes Associate Director, Quality Assurance (posted on April 7 2026).
Jim Mackaness, Chief Financial Officer, will leave the company on Mar. 31, 2026 (posted on February 27 2026).
Jennifer Fulk will join the company as Chief Financial Officer on Mar. 31, 2026 (posted on February 27 2026).

Click here to view some more movements at Soleno Therapeutics

Popular executive movements at Neurocrine Biosciences

Andrew Ratz, who was Senior Vice President, Drug Development, Delivery and Device, is promoted to Chief Technical Operations Officer (posted on March 18 2026).
Mike Sibley has joined the company as Senior Vice President and General Manager, Neuropsychiatry Franchise (posted on October 7 2025).

Create your alert
to follow the executive moves at Soleno Therapeutics.